Ocular Operating Cycle from 2010 to 2026
| OCUL Stock | USD 7.78 0.75 10.67% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 413.75375113 | Current Value 470.57 | Quarterly Volatility 527.20895087 |
Check Ocular Therapeutix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ocular Therapeutix's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.2 M, Interest Expense of 12.4 M or Selling General Administrative of 67.6 M, as well as many indicators such as Price To Sales Ratio of 41.67, Dividend Yield of 0.0 or PTB Ratio of 3.65. Ocular financial statements analysis is a perfect complement when working with Ocular Therapeutix Valuation or Volatility modules.
Ocular | Operating Cycle | Build AI portfolio with Ocular Stock |
Historical Operating Cycle data for Ocular Therapeutix serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Ocular Therapeutix represents a compelling investment opportunity.
Latest Ocular Therapeutix's Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Ocular Therapeutix over the last few years. It is Ocular Therapeutix's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ocular Therapeutix's overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Ocular Operating Cycle Regression Statistics
| Arithmetic Mean | 588.58 | |
| Geometric Mean | 430.79 | |
| Coefficient Of Variation | 89.57 | |
| Mean Deviation | 395.60 | |
| Median | 382.74 | |
| Standard Deviation | 527.21 | |
| Sample Variance | 277,949 | |
| Range | 1.5K | |
| R-Value | (0.65) | |
| Mean Square Error | 170,745 | |
| R-Squared | 0.42 | |
| Significance | 0 | |
| Slope | (67.99) | |
| Total Sum of Squares | 4.4M |
Ocular Operating Cycle History
About Ocular Therapeutix Financial Statements
Ocular Therapeutix investors utilize fundamental indicators, such as Operating Cycle, to predict how Ocular Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 413.75 | 470.57 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Ocular Therapeutix Correlation against competitors. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. Anticipated expansion of Ocular directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ocular Therapeutix assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.42) | Revenue Per Share | Quarterly Revenue Growth (0.22) | Return On Assets | Return On Equity |
Ocular Therapeutix's market price often diverges from its book value, the accounting figure shown on Ocular's balance sheet. Smart investors calculate Ocular Therapeutix's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Ocular Therapeutix's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Ocular Therapeutix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ocular Therapeutix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.